Results 11 to 20 of about 208,633 (265)
Checkpoint Inhibitors and Hepatotoxicity [PDF]
Biomedicines, 2021 Uncontrolled immune response to a pathogen or any protein can lead to tissue damage and autoimmune diseases, that represent aberrant immune responses of the individual to its own cells and/or proteins.
Stephen D. H. Malnick +2 more
doaj +3 more sources
Negative Immune Checkpoint Inhibitors
PharmaceuticsCheckpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate ...
Magda Drewniak-Świtalska +2 more
doaj +3 more sources
Immune checkpoint inhibitors [PDF]
Journal of Experimental Medicine, 2021 Three papers by James Allison and Tasuku Honjo published in JEM between 1995 and 2000 crystallized seminal insights into the role of CTLA-4 and PD-1 in immunosuppression (Krummel and Allison. 1995. J. Exp. Med.https://doi.org/10.1084/jem.182.2.459; van Elsas et al. 1999. J. Exp. Med.https://doi.org/10.1084/jem.190.3.355; Freeman et al. 2000. J.
Kroemer, Guido, Zitvogel, Laurence
openaire +3 more sources
Checkpoint Inhibitors and the Gut [PDF]
Journal of Clinical Medicine, 2022 Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies.
Tuan Tran +2 more
openaire +3 more sources
Immune Checkpoint Inhibitors and the Heart [PDF]
Frontiers in Cardiovascular Medicine, 2021 Immune checkpoint inhibitors (ICIs) represent a break-through treatment for a large number of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for primary tumours and for metastases, adjuvant/neo-adjuvant therapy.
Diana Larisa Mocan-Hognogi +11 more
openaire +3 more sources
Deutsches Ärzteblatt international, 2019 Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) antibodies can prolong the survival of cancer patients, but it also induces autoimmune side effects in 86-96% of patients by activating the immune system.
Lucie, Heinzerling +4 more
openaire +2 more sources
Immune checkpoint inhibitors in melanoma [PDF]
The Lancet, 2021 Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and anti-PD-1 antibodies, have revolutionised the management of many cancers, particularly advanced melanoma, for which tumour regression and long-term durable cancer control ...
Matteo S, Carlino +2 more
openaire +4 more sources
Checkpoint inhibitors and arthritis [PDF]
Annals of the Rheumatic Diseases, 2019 It was with interest that we read the article by Belkhir et al 1 in the recent Annals of Rheumatic Disease . The article described the first report of rheumatoid arthritis (RA) and polymyalgia rheumatica developing after the use of immune checkpoint inhibitors to treat a variety of cancers.
Nicholas, Manolios, Leslie, Schrieber
openaire +2 more sources
Keeping Checkpoint Inhibitors in Check [PDF]
JAMA Network Open, 2019 No ...
Catenacci, Daniel V.T. +2 more
openaire +3 more sources
Structure and Optimization of Checkpoint Inhibitors [PDF]
Cancers, 2019 With the advent of checkpoint inhibitor treatment for various cancer types, the optimization of drug selection, pharmacokinetics and biomarker assays is an urgent and as yet unresolved dilemma for clinicians, pharmaceutical companies and researchers.
Picardo, Sarah L. +2 more
openaire +4 more sources